Floatz logo

MIDAZOLAM

Choledocholithiasis

National University of MalaysiaSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Choledocholithiasis cohort.

Asset / SponsorPhaseRating
Meperidine
National University of Malaysia
Phase 4BBB
ETOMIDATE
Cheju Halla General Hospital
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
National University of Malaysia
Phase 2B
Gentamycin
National University of Malaysia
Phase 2CCC
CEFOXITIN
Yonsei University
N/AD

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →